All relevant data generated or analyzed during this study are included in the manuscript.

Introduction {#sec001}
============

Type 2 diabetes (DM) is a heterogeneous disorder of glucose metabolism characterized by both insulin resistance and pancreatic β-cell dysfunction. Catecholamines (CAs) are known to be among the factors involved in the pathophysiology of DM, as shown by the study of pathologic conditions, such as pheochromocytoma.\[[@pone.0228787.ref001]--[@pone.0228787.ref004]\] In cases of pheochromocytoma, glucose intolerance is often present,\[[@pone.0228787.ref001]--[@pone.0228787.ref004]\] and an excess of CAs appears to be the cause.\[[@pone.0228787.ref001], [@pone.0228787.ref005]--[@pone.0228787.ref010]\] However, the mechanisms leading to the glucose intolerance that characterizes pheochromocytoma have not been fully determined. Hyperinsulinemic-euglycemic clamp studies have shown that insulin resistance underpins the glucose intolerance present in patients with pheochromocytoma,\[[@pone.0228787.ref009],[@pone.0228787.ref011]\] but another recent study, which evaluated the effects of surgical removal of pheochromocytomas on glucose metabolism showed that impaired insulin secretion is a primary cause of the associated impairment in glucose tolerance.\[[@pone.0228787.ref010]\] In addition, although CAs have been shown to inhibit insulin secretion *via* α2 receptors on pancreatic β-cell,\[[@pone.0228787.ref012]--[@pone.0228787.ref015]\] they have also been shown to increase insulin resistance through α1 and the β receptors.\[[@pone.0228787.ref008],[@pone.0228787.ref009]\] Furthermore, adrenaline has a higher affinity for α2 receptors than noradrenaline.\[[@pone.0228787.ref002],[@pone.0228787.ref016]\] Therefore, the mechanisms whereby CAs reduce insulin secretion and increase insulin resistance differ, and adrenaline and noradrenaline (two principal CAs), may affect glucose metabolism differently.

Differing associations of the urinary concentrations of metanephrine (U-M) and normetanephrine (U-NM), metabolites of adrenaline and noradrenaline, respectively, with glucose intolerance have recently been reported. \[[@pone.0228787.ref017]\] In this study, which evaluated the relationship between changes in homeostatic model assessment (HOMA) indices and changes in U-M and U-UM concentrations resulting from the surgical removal of pheochromocytomas, the improvement in U-M concentrations was positively associated with the improvement in HOMA-β, an index representing insulin secretion; while the improvement of U-NM concentrations was positively associated with the improvement in HOMA-R, an index representing insulin resistance. Therefore, U-M and U-NM concentrations may reflect different risks for diabetes, at least in the presence of pathologic conditions, such as pheochromocytoma.

However, the relationships between the concentrations of these metabolites and glucose metabolism have not been assessed under physiologic conditions. Namely, it is unknown whether U-M and U-NM concentrations are associated with insulin secretion and/or insulin resistance under physiologic conditions, and how. Therefore, to address these questions, we aimed to evaluate the relationships of U-M and U-MN levels within the physiological range with glucose metabolism in a general population.

Materials and methods {#sec002}
=====================

Participants {#sec003}
------------

Participants were recruited from the Iwaki study, a health promotion study of Japanese people of over 20 years of age that aims to prevent lifestyle-related diseases and prolong lifespan. The study is conducted annually in the Iwaki area of the city of Hirosaki in Aomori Prefecture, northern Japan.\[[@pone.0228787.ref018],[@pone.0228787.ref019]\] Of the 1,148 individuals who participated in the Iwaki study in 2016, the following individuals were excluded from the present study: 330 who were taking drugs that affect serum catecholamine concentrations (i.e. α- and/or β-- blockers), five with incomplete clinical data, 78 with diabetes, and two with fasting blood glucose levels \< 63 mg/dl or \>140 mg/dl to better evaluate HOMA indices. After these exclusions, 733 individuals (320 men, 413 women) aged 52.1 ± 15.1 years were included in our study.

This study was approved by the Ethics Committee of the Hirosaki University School of Medicine (No. 2016--028 (approved at may 27, 2016)), and was conducted in accordance with the recommendations of the Declaration of Helsinki. Written informed consent was obtained from all the participants.

Measurements made {#sec004}
-----------------

Blood samples were collected in the morning from a peripheral vein under fasting conditions, while participants were in a supine position. All laboratory testing was performed in a commercial laboratory (LSI Medience Co., Tokyo, Japan), in accordance with the instructions of the vendors. U-M and U-NM concentrations were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The following clinical characteristics were also measured: height, body weight, body mass index, fasting blood glucose, fasting serum insulin, glycated hemoglobin (HbA1c), systolic blood pressure, diastolic blood pressure, and serum total cholesterol, triglyceride, high-density lipoprotein-cholesterol, uric acid, urea nitrogen, and creatinine. HbA1c (%) is expressed using the National Glycohemoglobin Standardization Program value. Insulin resistance and secretion were assessed by homeostasis model assessments, using fasting blood glucose and insulin concentrations (HOMA-R and HOMA-β). Diabetes was defined according to the 2010 Japan Diabetes Society criterion (fasting blood glucose levels ≥ 126 mg/dL).\[[@pone.0228787.ref020]\] In subjects whose fasting blood glucose concentrations were not measured, diabetes was defined by an HbA1c concentrations ≥ 6.5%. Those taking medication for diabetes were also defined as having diabetes. Hypertension was defined by a blood pressure ≥ 140/90 mmHg or the use of anti-hypertensive therapy. Dyslipidemia was defined by a LDL cholesterol of ≥ 120 mg/dL, an HDL cholesterol of \< 40 mg/dL, a triglyceride of ≥ 150 mg/dL, or the use of anti-hyperlipidemic therapy. Alcohol intake status (current or non-drinker) and smoking habits (never, past, or current) were determined using a questionnaire.

Statistical methods {#sec005}
-------------------

Clinical characteristics are summarized using means ± SD. The statistical significance of difference between two groups (parametric) and case-control associations between groups (nonparametric) were assessed using analysis of variance (ANOVA) and the χ^2^ test, respectively. Correlations between HOMA indices and clinical characteristics, including U-M and U-NM concentrations, were assessed using linear regression analysis. The relationships of U-M and U-NM concentrations with insulin secretion and insulin resistance were evaluated using multiple logistic regression analysis, with adjustment for factors found to be associated with the indices using univariate regression analysis. The relationship between U-NM concentrations and insulin resistance, defined on the basis of HOMA-R (≥1.6), was calculated using multiple logistic regression analysis with adjustment for factors found to be associated with insulin resistance using univariate regression analysis. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off value for U-NM that would predict increased insulin resistance. For statistical analyses, HOMA indices, serum creatinine, and U-M and U-NM, were log~10~-transformed to approximate a normal distribution. P\<0.05 was accepted as representing statistical significance. All analyses were performed using JMP Pro version 14.0 (SAS Institute Japan Ltd., Tokyo, Japan).

Results {#sec006}
=======

Clinical characteristics of the study subjects {#sec007}
----------------------------------------------

The clinical characteristics of the participants, classified according to sex, are shown in [Table 1](#pone.0228787.t001){ref-type="table"}. Their mean ages were 50.2 ± 15.2 years for men and 53.5 ± 14.9 years for women. Most clinical characteristics significantly differ between men and women, and urinary NM and M concentrations (mg/g creatinine) were significantly lower in men than women (0.16 ± 0.06 *vs*. 0.22 ± 0.09, and 0.11 ± 0.04 *vs*. 0.12 ± 0.05, respectively).

10.1371/journal.pone.0228787.t001

###### Clinical characteristics of the participants, classified according to sex.

![](pone.0228787.t001){#pone.0228787.t001g}

  Characteristics                          Men          Women        p
  ---------------------------------------- ------------ ------------ -------------
  **Number**                               320          413          **-**
  **Age (yr)**                             50.2±15.2    53.5±14.9    0.004\*\*
  **Height (cm)**                          169.2±6.7    155.8±6.3    \<0.001\*\*
  **Body weight (kg)**                     67.6±10.0    53.7±8.4     \<0.001\*\*
  **Body mass index (kg/m2)**              23.6±3.0     22.1±3.2     \<0.001\*\*
  **Fat (%)**                              19.9±5.6     29.8±6.8     \<0.001\*\*
  **Urinary NM (mg/gCr)**                  0.16±0.06    0.22±0.09    \<0.001\*\*
  **Urinary M (mg/gCr)**                   0.11±0.04    0.12±0.05    0.001\*\*
  **Fasting plasma glucose (mg/dl)**       89.9±9.9     86.9±9.7     \<0.001\*\*
  **HbA1c (%)**                            5.71±0.33    5.73±0.31    0.38
  **Fasting serum insulin: IRI (μU/ml)**   5.00±2.69    5.11±2.66    0.59
  **HOMA-R**                               1.13±0.65    1.12±0.68    0.92
  **HOMA-β**                               76.7±71.8    84.7±45.2    0.066
  **Systolic blood pressure (mmHg)**       124.4±16.5   122.2±18.5   0.097
  **Diastolic blood pressure (mmHg)**      77.0±12.1    73.3±12.2    \<0.001\*\*
  **LDL cholesterol (mg/dl)**              116.1±27.0   117.8±29.5   0.423
  **Triglyceride (mg/dl)**                 119.7±77.8   80.2±42.7    \<0.001\*\*
  **HDL cholesterol (mg/dl)**              58.5±17.3    69.5±16.5    \<0.001\*\*
  **Serum albumin (g/dl)**                 4.57±0.29    4.45±0.29    \<0.001\*\*
  **Serum uric Acid (mg/dl)**              6.09±1.22    4.42±1.00    \<0.001\*\*
  **Serum urea Nitrogen (mg/dl)**          14.6±4.1     13.9±4.1     0.012\*
  **Serum creatinin (mg/dl)**              0.84±0.17    0.63±0.12    \<0.001\*\*
  **Hypertension: n (%)**                  118(36.9)    128(31.0)    0.098
  **Dyslipidemia: n (%)**                  139(43.4)    171(41.4)    0.60
  **Drinking alcohol: n (%)**              233(72.8)    130(31.5)    \<0.001\*\*
  **Smoking (Never/ Past/ Current):n**     125/88/107   313/54/46    \<0.001\*\*

P\<0.05 and \<0.01 are indicated by \* and \*\*, respectively. Data are mean±SD or number of subjects (%).

Relationships of urinary NM and M concentrations with HOMA indices {#sec008}
------------------------------------------------------------------

The univariate correlations between the clinical characteristics and HOMA indices (R and β) are shown in [Table 2](#pone.0228787.t002){ref-type="table"}. Because many clinical characteristics such as age, sex, BMI, body fat percentage, blood pressure, HbA1c, and serum lipid, uric acid, and urea nitrogen concentrations were found to be correlated with HOMA indices, these factors were used as covariates for the adjustment of further analyses. Although univariate regression analyses revealed significant correlations between both U-NM and U-M and HOMA-β (β = -0.154 p\<0.001, and β = -0.174, p\<0.001, respectively), adjustment for the variables that correlated with HOMA indices abolish these correlations (β = -0.031, p = 0.499, and β = -0.055, p = 0.135, respectively) ([Table 3](#pone.0228787.t003){ref-type="table"}). In contrast, the correlation between U-NM and HOMA-R identified in the univariate regression analyses (β = 0.132, p\<0.001) remained significant even after these adjustments (β = 0.107, p = 0.007), whereas U-M did not correlate with HOMA-R (univariate: β = −0.067 p = 0.068; multivariate: β = 0.037, p = 0.276) ([Table 4](#pone.0228787.t004){ref-type="table"}).

10.1371/journal.pone.0228787.t002

###### Factors correlated with HOMA indices.

![](pone.0228787.t002){#pone.0228787.t002g}

  Characteristics                         R        β                      
  --------------------------------------- -------- ------------- -------- -------------
  **Sex (F/M)**                           0.004    0.921         0.165    \<0.001\*\*
  **Age (yr)**                            0.163    \<0.001\*\*   -0.301   \<0.001\*\*
  **Height (cm)**                         -0.066   0.074         -0.013   0.721
  **Body weight (kg)**                    0.344    \<0.001\*\*   0.116    0.002\*
  **Body mass index (kg/m**^**2**^**)**   0.507    \<0.001\*\*   0.165    \<0.001\*\*
  **Fat (%)**                             0.404    \<0.001\*\*   0.235    \<0.001\*\*
  **Urinary NM (mg/gCr)**                 0.132    \<0.001\*\*   -0.154   \<0.001\*\*
  **Urinary M (mg/gCr)**                  -0.067   0.068         -0.174   \<0.001\*\*
  **HbA1c (%)**                           0.306    \<0.001\*\*   -0.198   \<0.001\*\*
  **Systolic blood pressure (mmHg)**      0.279    \<0.001\*\*   -0.132   \<0.001\*\*
  **Diastolic blood pressure (mmHg)**     0.220    \<0.001\*\*   -0.081   0.029\*
  **LDL cholesterol (mg/dl)**             0.111    0.003\*       -0.068   0.066
  **Triglyceride (mg/dl)**                0.273    \<0.001\*\*   0.105    0.005\*\*
  **HDL cholesterol (mg/dl)**             -0.244   \<0.001\*\*   -0.110   0.003\*\*
  **Serum albumin (g/dl)**                0.023    0.540         0.102    0.006\*\*
  **Serum uric Acid (mg/dl)**             0.164    \<0.001\*\*   -0.061   0.099
  **Serum urea Nitrogen (mg/dl)**         0.093    0.011\*       -0.165   \<0.001\*\*
  **Serum creatinin (mg/dl)**             0.024    0.513         -0.055   0.135
  **Hypertension: n (%)**                 0.272    \<0.001\*\*   -0.118   0.001\*
  **Dyslipidemia: n (%)**                 0.251    \<0.001\*\*   0.023    0.538
  **Drinking alcohol: n (%)**             -0.107   0.004\*\*     -0.144   \<0.001
  **Smoking (Never/ Past/ Current):n**    -0.138   \<0.001\*     -0.029   0.434

P\<0.05 and \<0.01 are indicated by \* and \*\*, respectively. Data are mean±SD or number of subjects (%).

10.1371/journal.pone.0228787.t003

###### Correlations of urinary NM and M concentrations with HOMA indices.

![](pone.0228787.t003){#pone.0228787.t003g}

                   R[^\#1^](#t003fn001){ref-type="table-fn"}   β[^\#2^](#t003fn002){ref-type="table-fn"}                                                       
  ---------------- ------------------------------------------- ------------------------------------------- ------- ----------- -------- ------------- -------- -------
  **Urinary NM**   0.132                                       \<0.001\*\*                                 0.107   0.007\*\*   -0.154   \<0.001\*\*   -0.031   0.499
  **Urinary M**    -0.067                                      0.068                                       0.037   0.276       -0.174   \<0.001\*\*   -0.055   0.135

\#1: Adjusted for age, body mass index, glycated hemoglobin (HbA1c), serum triglyceride, uric acid, and urea nitrogen, hypertension, alcohol drinking, and smoking.

\#2: Adjusted for age, sex, body fat percentage, HbA1c, systolic blood pressure, serum high-density lipoprotein-cholesterol, albumin, and urea nitrogen, and alcohol drinking. *P*\<0.05 and \<0.01 are indicated by \* and \*\*, respectively.

10.1371/journal.pone.0228787.t004

###### Risk of insulin resistance associated with urinary NM concentration.

![](pone.0228787.t004){#pone.0228787.t004g}

                    Univariate   Multiple factors adjusted                                                 
  ----------------- ------------ --------------------------- ----------------- ---------- ---------------- ---------------
  **Upper alone**   **2.48**     **1.48--4.14**              **\<0.001\*\***   **2.65**   **1.42--4.95**   **0.002\*\***
  **Whole**         **2.80**     **1.82--4.29**              **\<0.001\*\***   **2.73**   **1.34--5.57**   **0.006\*\***

Odds ratios (ORs) with 95% confidence intervals (CIs) and p values are shown. Multiple factors were used to adjust the analyses: age, BMI, HbA1c, serum triglyceride, uric acid, and urea nitrogen, hypertension, alcohol drinking, and smoking. *P*\<0.05 and \<0.01 are indicated by \* and \*\*, respectively.

Association between high physiologic U-NM concentrations and increased insulin resistance {#sec009}
-----------------------------------------------------------------------------------------

To further evaluate the relationship between U-NM and insulin resistance, the participants were allocated to two groups on the basis of their U-NM concentrations (upper: ≥0.18 mg/g creatinine, lower: \<0.18 mg/g creatinine), because the relationship between U-NM and HOMA-R appeared to be J-shaped, with an inflection point in the mid-range of the U-NM levels ([Fig 1](#pone.0228787.g001){ref-type="fig"}). The correlation between U-NM and HOMA-R was stronger in the upper group (univariate: β = 0.197, p\<0.001; multivariate: β = 0.152, p = 0.002), but abolished in the lower group (univariate: β = −0.022 p = 0.667; multivariate: β = -0.018, p = 0.714). Then, using the upper group alone, we then evaluated the risk of increased insulin resistance (defined as HOMA-R ≥1.6) according to U-NM concentration, and determined the optimal cut-off value of U-NM for the prediction of increased insulin resistance using ROC analyses (area under the curve: 0.608; sensitivity: 0.558; specificity: 0.662). Using the optimal cut-off value of U-NM concentration (0.2577 mg/g creatinine), those at risk had an odds ratio (OR) of 2.65 (p = 0.002, confidence interval (CI): 1.42--4.95) after adjustment for the variables described above. Moreover, even when the all the samples were analyzed, participants with U-NM concentration above the cut-off value were significantly at risk for increased insulin resistance after adjustment for the confounding factors (OR: 2.73, p = 0.006, 95%CI: 1.34--5.57).

![Correlation between urinary normetanephrine concentration and insulin resistance, assessed using the homeostasis model (HOMA-R).\
Linear regression lines are shown for the entire cohort (red line) and halves of the cohort, divided on the basis of their urinary normetanephrine concentration (upper: \> 0.18 mg/g creatinine; lower: \< 0.18 mg/g creatinine) (green line).](pone.0228787.g001){#pone.0228787.g001}

Taken together, these results indicate that higher U-NM concentrations are significantly associated with increased insulin resistance, but not decreased insulin secretion, in a general Japanese population.

Discussion {#sec010}
==========

In this cross-sectional study of a general Japanese population, we found that U-NM concentrations within the physiologic range significantly correlate with HOMA-R, but not with HOMA-β. The associations between CA concentrations, including those of U-NM and U-M, and the indices, reflecting glucose metabolisms such as HOMA indices, have frequently been reported in patients with pheochromocytomas.\[[@pone.0228787.ref001]--[@pone.0228787.ref010],[@pone.0228787.ref012]\] In these patients, CA concentrations has been shown to be positively associated with both insulin resistance and impairment of insulin secretion, both of which have been shown to be primary causes of the impaired glucose tolerance in such patients.\[[@pone.0228787.ref009],[@pone.0228787.ref010]\] However, these relationship had not been well studied in individuals with physiologic CA concentrations or healthy individuals. The results observed here indicate that higher U-NM concentration is a risk for insulin resistance, but not for insulin secretion, when the concentrations are within the physiologic range.

As described previously, the type of CA present in excess determined how glucose metabolism is impacted, because the mechanisms whereby CA leading to decreased insulin secretion and increased insulin resistance differ,\[[@pone.0228787.ref008],[@pone.0228787.ref009],[@pone.0228787.ref012]--[@pone.0228787.ref015]\] and adrenaline has higher affinity for α2 receptors on pancreatic β-cell than noradrenaline.\[[@pone.0228787.ref001],[@pone.0228787.ref016]\] A previous study of patients with pheochromocytoma found that U-NM and U-M concentrations are differently associated with insulin resistance and insulin secretion: U-M is positively associated with impairment in insulin secretion, but not with insulin resistance, while U-NM is negatively associated with impairment of insulin secretion and positively associated with insulin resistance.\[[@pone.0228787.ref017]\] In the current study of people with CA concentrations within the physiologic range, the relationship between CAs and HOMA indices also differed according to the type of CA, with U-NM concentrations being significantly associated with insulin resistance, but no other association being identified. Taken together, these findings suggest that noradrenaline, but not adrenaline, excess causes insulin resistance at concentrations within the physiologic range, and when their concentrations reach the pathologic range, adrenaline has the most significant negative effect on insulin secretion.

Because this was a cross-sectional study, we cannot infer a cause and effect relationship, so the positive correlation between U-NM and HOMA-R does not necessarily imply that NM increases insulin resistance. We believe that plasma noradrenalin concentrations within the physiologic range do not have substantial metabolic effects, but rather reflect sympathetic nerve activity. Systemic concentrations of CAs, particularly adrenaline and noradrenaline, appear to represent adrenal function and sympathetic nerve activity, respectively, especially under physiologic conditions.\[[@pone.0228787.ref021]\] However, because plasma noradrenaline has been shown to be only a small fraction of the quantity secreted from sympathetic nerve terminals,\[[@pone.0228787.ref022], [@pone.0228787.ref023]\] plasma noradrenaline concentration is thought to be a less sensitive indicator of overall sympathetic activity.\[[@pone.0228787.ref023]\] Here, we used U-M and U-NM concentrations to represent plasma CA concentrations, because these concentrations are known to be stable.\[[@pone.0228787.ref016]\] Nevertheless, U-MN may, at least in part, reflect sympathetic nerve activity, because the association between high sympathetic activity and insulin resistance has been well documented.\[[@pone.0228787.ref021], [@pone.0228787.ref024], [@pone.0228787.ref025]\]

Our study has both strengths and limitations. Significant strengths are that statistical adjustments were made for multiple factors that could confound the results, and a relatively large sample of the general population was studied, which allowed us to evaluate the relationships between CAs and insulin secretion without any influence of compensatory increases in insulin secretion. Contrary, adjustment for multiple factors can reduce statistical power, and, thus, may also be a limitation. However, statistical power to determine the difference in the frequencies of insulin resistance between the subjects above and below the cut-off value for U-NM determined using SampSize software (<http://sampsize.sourceforge.net/iface/index.html>) was 99.8% to detect an OR of 2.73 for insulin resistance at a significance level of 0.05, and, thus, the issue does not seem to be substantial. Furthermore, we excluded individuals taking medication that could have affected serum CA concentrations, and those with fasting blood glucose concentrations \< 63 mg/dl or \> 140 mg/dl, to better evaluate HOMA indices. Such exclusions made the sample suitable for interrogation of the relationships between CAs and HOMA indices.

Several limitations should be mentioned. Firstly, the participants had enrolled in a health promotion study, rather than a routine health check study, and may therefore have been more invested in keeping themselves healthy than the wider general population. Secondly, 415 of the original 1,148 participants were excluded in the present study, which may have led to selection bias. Taken together, these factors may imply that the participants did not accurately represent the general population. Thirdly, we used HOMA indices (R and β) as surrogates for insulin resistance and secretion, respectively. However, because both indices are calculated using fasting concentrations of insulin and glucose, they are closely related. Thus, when insulin resistance increases, insulin secretion increases in compensation, meaning that both HOMA-R and β increase. Therefore, any associations with HOMAs should be interpreted cautiously, as in the case of the study reporting associations of U-NM with both insulin resistance and insulin secretion, although the association between U-NM and insulin resistance seemed to be primary.\[[@pone.0228787.ref017]\] However, in the present study, we did not observe such conflicting results. Fourthly, we evaluated insulin secretion using HOMA-β to represent insulin secretion in the fasting state, and did not measure any indices of glucose-stimulated insulin secretion. This is a limitation of the study, because suppression of the acute insulin secretory response has been reported to be the principal effect of adrenaline.\[[@pone.0228787.ref010], [@pone.0228787.ref015], [@pone.0228787.ref026]\] Finally, because the study was cross-sectional, rather than a cohort study, we could not determine whether higher U-NM can predict the risk of future glucose intolerance or diabetes.

In conclusion, higher U-NM levels within the physiologic range are significantly associated with insulin resistance, but not with insulin secretion, in a general Japanese population. These results suggest that higher U-NM levels are a risk factor for insulin resistance, and thus for future diabetes. This possibility should be tested in future prospective studies.

10.1371/journal.pone.0228787.r001
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2\. As for description, authors must be more careful. Authors should modify below, and then check whole manuscript once more.

Sentence 31 "normetanephrine (U-NM) and metanephrine (U-M) "should be modified to "urinary normetanephrine (U-NM) and metanephrine (U-M)".

Sentence 44 "HOMA-B" is incorrect, I think. Authors should modify this to "HOMA-R".

Sentence 67 "throughα 1" should be modified to "through α1".

Sentence 73 "normetanephrin" should be modified to "normetanephrine".

Sentence 76 "changes in U-NM and U-MN concentrations" should be modified to "changes in U-M and U-NM concentrations".

Sentence 212, 215, 219 Authors wrote "CA concentrations", "CA concentration", and "CAs concentrations" respectively. Authors should unify the writing.

Reviewer \#2: I enjoyed reading this manuscript, in particular, the detailed analyses using appropriate statistical models, and the explanation of the results based on the analyses. However, I have some concerns.

\(a\) NO sample size/power statements are provided, and that needs to be justified wrt. the sample size of the analysis.

\(b\) Results on logistic regression should be reported in terms of effects sizes, p-values AND an indication of the uncertainty (typically, 95% confidence intervals, henceforth, CIs), given that p-values and CIs provide complementary information; see article <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689604/>

Furthermore, results should be explained that way.

\(c\) The title of the paper says \"General population\"; however, the target population is Japanese. This can be confusing to readers!, given that the authors are not consider a global population (spanning across all continents). The title should be revised.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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13 Jan 2020

Dear reviewer \#1:

Thank you very much for having reviewed our manuscript entitled \" Association between higher urinary normetanephrine and insulin resistance in a general population: PONE-D-19-29066\". We have changed our manuscript to fulfill your criticisms as much as possible, and in most cases, I just changed as you requested. In any case, we beg your generosity to kindly feel satisfied with my responses. The details of the responses to each criticism were written below.

This article is very interesting because authors investigated association between urinary metanephrine/normetanephrine and insulin resistance/secretion in a large cohort. I think this study has enough novelty and priority. Almost all of investigations and analyses were appropriate and performed adequately, but I would like to suggest authors to confirm some points.

\-\-\-\--I appreciate your evaluation.

1\. Authors quoted various accurate references, particularly about the relationship between catecholamines and glycemic characteristics. However, I would like you to check one sentence, which was very important. Authors of ref. 17 revealed differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma. In the article, authors of ref. 17 described "Regression analysis revealed that the improvement in HOMA-B from before to after surgery had a significant positive association with the improvement in urinary levels of metanephrine after surgery (P = 0.0286), and a significant negative association with the improvement in urinary levels of normetanephrine after surgery (P = 0.0248). The improvement in HOMA-IR did not show a positive association with the improvement in urinary levels of metanephrine but showed a significant positive association with the improvement in urinary levels of normetanephrine (P = 0.0001)" in Results of ref. 17. However, authors wrote "the improvement in U-M concentrations was \"negatively\" associated with the improvement in HOMA-B" (sentence 77-79). "the improvement in urinary metanephrine was "positively" associated with the improvement in HOMA-B" must be proper. In discussion, authors' description was proper (sentence 229-232), so I think authors miswrote. Authors should check ref. 17 again, and then modify this description.

\-\-\-\--Thanks for your pointing. We correct the miswriting as you pointed.

2\. As for description, authors must be more careful. Authors should modify below, and then check whole manuscript once more.

\-\-\-\--Thanks for your comments and I apologize such miswriting. We corrected as you suggested as follows.

Sentence 31 "normetanephrine (U-NM) and metanephrine (U-M) "should be modified to "urinary normetanephrine (U-NM) and metanephrine (U-M)".

\-\-\-\-\--Thanks. We corrected them as you mentioned.

Sentence 44 "HOMA-B" is incorrect, I think. Authors should modify this to "HOMA-R".

\-\-\-\-\-- Thanks. We corrected them as you mentioned.

Sentence 67 "throughα 1" should be modified to "through α1".

\-\-\-\-\-\-- Thanks. We corrected them as you mentioned.

Sentence 73 "normetanephrin" should be modified to "normetanephrine".

\-\-\-\-\-- Thanks. We corrected them as you mentioned.

Sentence 76 "changes in U-NM and U-MN concentrations" should be modified to "changes in U-M and U-NM concentrations".

\-\-\-\-- Thanks. We corrected them as you mentioned.

Sentence 212, 215, 219 Authors wrote "CA concentrations", "CA concentration", and "CAs concentrations" respectively. Authors should unify the writing.

\-\-\-\-\-- Thanks. We unified the words as "CA concentrations".

Dear reviewer \#2:

Thank you very much for having reviewed our manuscript entitled \" Association between higher urinary normetanephrine and insulin resistance in a general population: PONE-D-19-29066\". We have changed our manuscript to fulfill your criticisms as much as possible, and in most cases, I just changed as you requested. In any case, we beg your generosity to kindly feel satisfied with my responses. The details of the responses to each criticism were written below.

I enjoyed reading this manuscript, in particular, the detailed analyses using appropriate statistical models, and the explanation of the results based on the analyses. However, I have some concerns.

\-\-\-\--Thanks for your evaluation.

\(a\) NO sample size/power statements are provided, and that needs to be justified wrt. the sample size of the analysis.

\-\-\-\--Thanks for your comment. We added such statement in "discussion" as follows: Contrary, adjustment for multiple factors can .......statistical power...........was 99.8% to detect an OR of 2.73 for insulin resistance at a significance level of 0.05, .............

\(b\) Results on logistic regression should be reported in terms of effects sizes, p-values AND an indication of the uncertainty (typically, 95% confidence intervals, henceforth, CIs), given that p-values and CIs provide complementary information; see article <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689604/>

Furthermore, results should be explained that way.

\-\-\-\--Thanks for your comments. We added p values for the analyses in "Results".

\(c\) The title of the paper says \"General population\"; however, the target population is Japanese. This can be confusing to readers!, given that the authors are not consider a global population (spanning across all continents). The title should be revised.

\-\-\-\--Thanks for your comments. We corrected the title as follows:...in a Japanese population.

###### 

Submitted filename: PlosOne-NM-response to reviewers-2.docx

###### 

Click here for additional data file.
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Dear Dr. Daimon,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Tatsuo Shimosawa, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for addressing my concerns. The revised manuscript is suitable for publication. There were no points to be modify.

Reviewer \#2: The authors addressed my comments from the previous round adequately. I have no further comments. Can the authors provide some suggestions on how the real data can be accessed?

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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Dear Dr. Daimon:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Tatsuo Shimosawa

Academic Editor

PLOS ONE
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